Enhancing topical ruxolitinib delivery via emulgel for vitiligo: formulation development, in vitro release, skin permeation, and mechanistic effects on melanogenesis

Puntos clave

• Topical ruxolitinib delivery significantly improved melanogenesis when using an emulgel formulation, leading to better outcomes in vitiligo treatment.
• Release studies indicated a controlled in vitro release profile over a 24-hour period, establishing effective drug availability.
• Skin permeation tests demonstrated enhanced absorption of ruxolitinib through emulgel compared to conventional formulations, reaching deeper layers of skin.
• These findings highlight the potential of emulgel formulations for optimizing drug delivery in dermatological therapies, warranting further clinical validation.